Causes and pathogenesis of focal segmental glomerulosclerosis

Nature Reviews Nephrology

Volumn 11, Issue 2, 2015, Pages 76-87

  Fogo, Agnes B ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ 4; ANABOLIC AGENT; ANGIOTENSIN II; APOLIPOPROTEIN; APOLIPOPROTEIN L1; CALCINEURIN INHIBITOR; CD151 ANTIGEN; CD2 ASSOCIATED PROTEIN; CYCLOSPORIN; DEXAMETHASONE; INTEGRIN; INTERLEUKIN 2 RECEPTOR ALPHA; LAMININ GAMMA1; MICRORNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEPHRIN; PAMIDRONIC ACID; PHOSPHOLIPASE; PHOSPHOLIPASE C EPSILON 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; PODOCIN; RAPAMYCIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 1; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VITRONECTIN; WT1 PROTEIN;

AUTOPHAGY; B LYMPHOCYTE; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GENETIC RISK; GLOMERULOSCLEROSIS; HUMAN; NEPHRON; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RECURRENT DISEASE; REVIEW; ANIMAL; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; PATHOLOGY; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; RISK FACTORS;

EID: 84923186960     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2014.216     Document Type: Review

References (122)

1. Collins, A. J. et al. US Renal Data System 2010 Annual Data Report. Am. J. Kidney Dis. 57 (Suppl. 1), e1-e526 (2011).
2. D'Agati, V. D., Kaskel, F. J. & Falk, R. J. Focal segmental glomerulosclerosis. N. Engl. J. Med. 365, 2398-2411 (2011).
3. Hogan, J. & Radhakrishnan, J. The treatment of minimal change disease in adults. J. Am. Soc. Nephrol. 24, 702-711 (2013).
4. Verani, R. R. & Hawkins, E. P. Recurrent focal segmental glomerulosclerosis. A pathological study of the early lesion. Am. J. Nephrol. 6, 263-270 (1986).
5. Straatmann, C. et al. Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients. Pediatr. Transplant. 18, 29-34 (2014).
6. Gallon, L., Leventhal, J., Skaro, A., Kanwar, Y. & Alvarado, A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N. Engl. J. Med. 366, 1648-1649 (2012).
7. Vinai, M., Waber, P. & Seikaly, M. G. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr. Transplant. 14, 314-325 (2010).
8. D'Agati, V. D., Fogo, A. B., Bruijn, J. A. & Jennette, J. C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am. J. Kidney Dis. 43, 368-382 (2004).
9. Barisoni, L., Kriz, W., Mundel, P. & D'Agati, V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 10, 51-61 (1999).
10. Howie, A. J. & Brewer, D. B. Further studies on the glomerular tip lesion: early and late stages and life table analysis. J. Pathol. 147, 245-255 (1985).
11. Howie, A. J., Pankhurst, T., Sarioglu, S., Turhan, N. & Adu, D. Evolution of nephrotic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int. 67, 987-1001 (2005).
12. Stokes, M. B., Valeri, A. M., Markowitz, G. S. & D'Agati, V. D. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int. 70, 1783-1792 (2006).
13. Thomas, D. B. et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 69, 920-926 (2006).
14. IJpelaar, D. H. T. et al. Fidelity and evolution of recurrent FSGS in renal allografts. J. Am. Soc. Nephrol. 19, 2219-2224 (2008).
15. Canaud, G. et al. Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). Nephrol. Dial. Transplant. 25, 1321-1328 (2010).
16. Rossini, M. & Fogo, A. B. Interpreting segmental glomerular sclerosis. Curr. Diagnostic Pathol. 10, 1-10 (2004).
17. D'Agati, V. D. et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin. J. Am. Soc. Nephrol. 8, 399-406 (2013).
18. Mondini, A., Messa, P. & Rastaldi, M. P. The sclerosing glomerulus in mice and man: novel insights. Curr. Opin. Nephrol. Hypertens. 23, 239-244 (2014).
19. McCarthy, E. T., Sharma, M. & Savin, V. J. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 5, 2115-2121 (2010).
20. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
21. Jefferson, J. A. & Shankland, S. J. Has the circulating permeability factor in primary FSGS been found? Kidney Int. 84, 235-238 (2013).
22. Huang, J. et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int. 84, 366-372 (2013).
23. Bock, M. E., Price, H. E., Gallon, L. & Langman, C. B. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin. J. Am. Soc. Nephrol. 8, 1304-1311 (2013).
24. Franco Palacios, C. R. et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation 96, 394-399 (2013).
25. Meijers, B. et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 85, 636-640 (2014).
26. Sinha, A. et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 85, 649-658 (2014).
27. Kronbichler, A. et al. Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am. J. Nephrol. 39, 322-330 (2014).
28. Pollak, M. R. The genetic basis of FSGS and steroid-resistant nephrosis. Semin. Nephrol. 23, 141-146 (2003).
29. Gbadegesin, R. et al. Mutational analysis of NPHS2 and WT1 in frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr. Nephrol. 22, 509-513 (2007).
30. Gigante, M. et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol. Dial. Transplant. 24, 1858-1864 (2009).
31. Kim, J. M. et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 300, 1298-1300 (2003).
32. Barua, M. et al. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. Kidney Int. 83, 316-322 (2013).
33. Choi, H. J. et al. Familial focal segmental glomerulosclerosis associated with an ACTN4 mutation and paternal germline mosaicism. Am. J. Kidney Dis. 51, 834-838 (2008).
34. Ma, L. J. & Fogo, A. B. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int. 64, 350-355 (2003).
35. Laouari, D. et al. TGF-a mediates genetic susceptibility to chronic kidney disease. J. Am. Soc. Nephrol. 22, 327-335 (2011).
36. Papeta, N. et al. Prkdc participates in mitochondrial genome maintenance and prevents Adriamycin-induced nephropathy in mice. J. Clin. Invest. 120, 4055-4064 (2010).
37. Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183-2196 (2013).
38. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010).
39. Gebeshuber, C. A. et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat. Med. 19, 481-487 (2013).
40. Cavasin, M. A., Rhaleb, N. E., Yang, X. P. & Carretero, O. A. Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43, 1140-1145 (2004).
41. Zuo, Y. et al. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kidney Int. 84, 1166-1175 (2013).
42. Macconi, D. et al. MicroRNA-324-3p promotes renal fibrosis and is a target of ACE inhibition. J. Am. Soc. Nephrol. 23, 1496-1505 (2012).
43. Wu, J. et al. Downregulation of microRNA-30 facilitates podocyte injury and Is prevented by glucocorticoids. J. Am. Soc. Nephrol. 25, 92-104 (2014).
44. Shi, S. et al. Smad2-dependent downregulation of miR-30 is required for TGF-β-induced apoptosis in podocytes. PLoS ONE 8, e75572 (2013).
45. D'Agati, V. Pathologic classification of focal segmental glomerulosclerosis. Semin. Nephrol. 23, 117-134 (2003).
46. Markowitz, G. S., Nasr, S. H., Stokes, M. B. & D'Agati, V. D. Treatment with IFN-a,-β, or-y is associated with collapsing focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 5, 607-615 (2010).
47. Markowitz, G. S. et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J. Am. Soc. Nephrol. 12, 1164-1172 (2001).
48. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931-938 (2008).
49. Meehan, S. M. et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 65, 1192-1197 (1998).
50. Hunley, T. E., Fogo, A., Iwasaki, S. & Kon, V. Endothelin A receptor mediates functional but not structural damage in chronic cyclosporine nephrotoxicity. J. Am. Soc. Nephrol. 5, 1718-1723 (1995).
51. Fogo, A. B. The targeted podocyte. J. Clin. Invest. 121, 2142-2145 (2011).
52. Godel, M. et al. Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J. Clin. Invest. 121, 2197-2209 (2011).
53. Herlitz, L. C. et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J. Am. Soc. Nephrol. 21, 163-172 (2010).
54. Cohen, A. H. & Nast, C. C. HIV-associated nephropathy. A unique combined glomerular, tubular, and interstitial lesion. Mod. Pathol. 1, 87-97 (1988).
55. Marras, D. et al. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat. Med. 8, 522-526 (2002).
56. Medapalli, R. K., He, J. C. & Klotman, P. E. HIV-associated nephropathy: pathogenesis. Curr. Opin. Nephrol. Hypertens. 20, 306-311 (2011).
57. Zuo, Y. et al. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J. Am. Soc. Nephrol. 17, 2832-2843 (2006).
58. Zhong, J. et al. Expression of HIV-1 genes in podocytes alone can lead to the full spectrum of HIV-1-associated nephropathy. Kidney Int. 68, 1048-1060 (2005).
59. Kopp, J. B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129-2137 (2011).
60. Moudgil, A. et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int. 59, 2126-2133 (2001).
61. Hostetter, T. H., Olson, J. L., Rennke, H. G., Venkatachalam, M. A. & Brenner, B. M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am. J. Physiol. 241, F85-F93 (1981).
62. Anderson, S., Rennke, H. G. & Brenner, B. M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 77, 1993-2000 (1986).
63. Fogo, A. et al. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int. 38, 115-123 (1990).
64. Fogo, A., Yoshida, Y., Glick, A. D., Homma, T. & Ichikawa, I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J. Clin. Invest. 82, 322-330 (1988).
65. Barker, D. J. & Osmond, C. Low birth weight and hypertension. BMJ 297, 134-135 (1988).
66. Luyckx, V. A. et al. Effect of fetal and child health on kidney development and long-term risk of hypertension and kidney disease. Lancet 382, 273-283 (2013).
67. White, S. L. et al. Is low birth weight an antecedent of CKD in later life? A systematic review of observational studies. Am. J. Kidney Dis. 54, 248-261 (2009).
68. Hodgin, J. B., Rasoulpour, M., Markowitz, G. S. & D'Agati, V. D. Very low birth weight is a risk factor for secondary focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 4, 71-76 (2009).
69. Schulz, L. C. The Dutch Hunger Winter and the developmental origins of health and disease. Proc. Natl Acad. Sci. USA 107, 16757-16758 (2010).
70. Ikezumi, Y. et al. Low birthweight and premature birth are risk factors for podocytopenia and focal segmental glomerulosclerosis. Am. J. Nephrol. 38, 149-157 (2013).
71. Ma, J. et al. Effects of podocyte injury on glomerular development. Pediatr. Res. 62, 417-421 (2007).
72. Bertram, J. F., Douglas-Denton, R. N., Diouf, B., Hughson, M. D. & Hoy, W. E. Human nephron number: implications for health and disease. Pediatr. Nephrol. 26, 1529-1533 (2011).
73. Zimanyi, M. A. et al. Nephron number and individual glomerular volumes in male Caucasian and African American subjects. Nephrol. Dial. Transplant. 24, 2428-2433 (2009).
74. Hoy, W. E., Hughson, M. D., Singh, G. R., Douglas-Denton, R. & Bertram, J. F. Reduced nephron number and glomerulomegaly in Australian Aborigines: a group at high risk for renal disease and hypertension. Kidney Int. 70, 104-110 (2006).
75. Fogo, A. B. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int. Suppl. 75, S15-S21 (2000).
76. Wikstad, I., Celsi, G., Larsson, L., Herin, P. & Aperia, A. Kidney function in adults born with unilateral renal agenesis or nephrectomized in childhood. Pediatr. Nephrol. 2, 177-182 (1988).
77. Fowler, S. M. et al. Obesity-related focal and segmental glomerulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr. Nephrol. 24, 851-855 (2009).
78. Kambham, N., Markowitz, G. S., Valeri, A. M., Lin, J. & D'Agati, V. D. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 59, 1498-1509 (2001).
79. Schmid, H. et al. Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J. Am. Soc. Nephrol. 14, 2958-2966 (2003).
80. Xu, B. J. et al. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. J. Am. Soc. Nephrol. 16, 2967-2975 (2005).
81. Durvasula, R. V. & Shankland, S. J. The renin-angiotensin system in glomerular podocytes: mediator of glomerulosclerosis and link to hypertensive nephropathy. Curr. Hypertens. Rep. 8, 132-138 (2006).
82. Naito, T. et al. Angiotensin type 2 receptor actions contribute to angiotensin type 1 receptor blocker effects on kidney fibrosis. Am. J. Physiol. Renal Physiol. 298, F683-F691 (2010).
83. Wu, D. T., Bitzer, M., Ju, W., Mundel, P. & Bottinger, E. P. TGF-β concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J. Am. Soc. Nephrol. 16, 3211-3221 (2005).
84. Eddy, A. A. & Fogo, A. B. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J. Am. Soc. Nephrol. 17, 2999-3012 (2006).
85. Ma, L. J. & Fogo, A. B. PAI-1 and kidney fibrosis. Front. Biosci. (Landmark Ed.) 14, 2028-2041 (2009).
86. Fogo, A. B. Mechanisms of progression of chronic kidney disease. Pediatr. Nephrol. 22, 2011-2022 (2007).
87. Regele, H. M. et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 11, 403-412 (2000).
88. Giannico, G., Yang, H., Neilson, E. G. & Fogo, A. B. Dystroglycan in the diagnosis of FSGS. Clin. J. Am. Soc. Nephrol. 4, 1747-1753 (2009).
89. Giannico, G. et al. Dystroglycan patterns in FSGS variants. Lab. Invest. 91, 344A (2011).
90. Lasagni, L., Lazzeri, E., Shankland, S. J., Anders, H. J. & Romagnani, P. Podocyte mitosis-a catastrophe. Curr. Mol. Med. 13, 13-23 (2013).
91. Kriz, W., Gretz, N. & Lemley, K. V. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int. 54, 687-697 (1998).
92. Wharram, B. L. et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J. Am. Soc. Nephrol. 16, 2941-2952 (2005).
93. Matsusaka, T. et al. Podocyte injury damages other podocytes. J. Am. Soc. Nephrol. 22, 1275-1285 (2011).
94. Matsusaka, T. et al. Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection. Am. J. Physiol. Renal Physiol. 300, F792-F800 (2011).
95. Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129-1136 (2008).
96. Eremina, V. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest. 111, 707-716 (2003).
97. Shankland, S. J., Smeets, B., Pippin, J. W. & Moeller, M. J. The emergence of the glomerular parietal epithelial cell. Nat. Rev. Nephrol. 10, 158-173 (2014).
98. Lasagni, L. & Romagnani, P. Basic research: Podocyte progenitors and ectopic podocytes. Nat. Rev. Nephrol. 9, 715-716 (2013).
99. Shankland, S. J., Anders, H. J. & Romagnani, P. Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr. Opin. Nephrol. Hypertens. 22, 302-309 (2013).
100. Berger, K. et al. The regenerative potential of parietal epithelial cells in adult mice. J. Am. Soc. Nephrol. 25, 693-705 (2014).
101. Ueno, T. et al. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int. 83, 1065-1075 (2013).
102. Sugimoto, H. et al. Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc. Natl Acad. Sci. USA 103, 7321-7326 (2006).
103. Meyer-Schwesinger, C. et al. Bone marrow-derived progenitor cells do not contribute to podocyte turnover in the puromycin aminoglycoside and renal ablation models in rats. Am. J. Pathol. 178, 494-499 (2011).
104. Smeets, B. et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 22, 1262-1274 (2011).
105. Nagata, M., Nakayama, K., Terada, Y., Hoshi, S. & Watanabe, T. Cell cycle regulation and differentiation in the human podocyte lineage. Am. J. Pathol. 153, 1511-1520 (1998).
106. Sayyed, S. G. et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52, 2445-2454 (2009).
107. Shkreli, M. et al. Reversible cell-cycle entry in adult kidney podocytes through regulated control of telomerase and Wnt signaling. Nat. Med. 18, 111-119 (2012).
108. Niranjan, T. et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat. Med. 14, 290-298 (2008).
109. Fatima, H. et al. Parietal epithelial cell activation marker in early recurrence of FSGS in the transplant. Clin. J. Am. Soc. Nephrol. 7, 1852-1858 (2012).
110. Rizzo, P. et al. Nature and mediators of parietal epithelial cell activation in glomerulonephritides of human and rat. Am. J. Pathol. 183, 1769-1778 (2013).
111. Ren, G., Khusheim, M., Yang, H. & Fogo, A. B. Plasminogen activator inhibitor-1 (PAI-1) affects parietal epithelial cell (PECs) transition. Lab. Invest. 93, 391A (2013).
112. Palma Diaz, M. et al. Expansion of the parietal cell compartment in collapsing glomerulopathy. Lab. Invest. 91, 349A (2011).
113. Sakamoto, K. et al. The direction and role of phenotypic transition between podocytes and parietal epithelial cells in focal segmental glomerulosclerosis. Am. J. Physiol. Renal Physiol. 306, F98-F104 (2014).
114. Wanner, N. et al. Unraveling the role of podocyte turnover in glomerular aging and injury. J. Am. Soc. Nephrol. 25, 707-716 (2014).
115. Pippin, J. W. et al. Cells of renin lineage are progenitors of podocytes and parietal epithelial cells in experimental glomerular disease. Am. J. Pathol. 183, 542-557 (2013).
116. Zhang, J. et al. De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy. Am. J. Physiol. Renal Physiol. 302, F571-F580 (2012).
117. Wu, L. et al. Rapamycin upregulates autophagy by inhibiting the mTOR-ULK1 pathway, resulting in reduced podocyte injury. PLoS ONE 8, e63799 (2013).
118. Chen, J., Chen, M. X., Fogo, A. B., Harris, R. C. & Chen, J. K. mVps34 deletion in podocytes causes glomerulosclerosis by disrupting ntracellular vesicle trafficking. J. Am. Soc. Nephrol. 24, 198-207 (2013).
119. Huber, T. B. et al. Emerging role of autophagy in kidney function, diseases and aging. Autophagy 8, 1009-1031 (2012).
120. Narita, M. et al. Spatial coupling of mTOR and autophagy augments secretory phenotypes. Science 332, 966-970 (2011).
121. Zoja, C, Benigni, A. & Remuzzi, G. Cellular responses to protein overload: key event in renal disease progression. Curr. Opin. Nephrol. Hypertens. 13, 31-37 (2004).
122. Peired, A. et al. Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J. Am. Soc. Nephrol. 24, 1756-1768 (2013).